Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway

J Cell Physiol. 2018 Mar;233(3):2526-2536. doi: 10.1002/jcp.26128. Epub 2017 Sep 4.

Abstract

Extracellular nucleotides can regulate cell proliferation in both normal and tumorigenic tissues. Here, we studied how extracellular nucleotides regulate the proliferation of ZL55 cells, a mesothelioma-derived cell line obtained from bioptic samples of asbestos-exposed patients. ADP and 2-MeS-ADP inhibited ZL55 cell proliferation, whereas ATP, UTP, and UDP were inactive. The nucleotide potency profile and the blockade of the ADP-mediated inhibitory effect by the phospholipase C inhibitor U-73122 suggest that P2Y1 receptor controls ZL55 cell proliferation. The activation of P2Y1 receptor by ADP leads to activation of intracellular transduction pathways involving [Ca2+ ]i , PKC-δ/PKC-α, and MAPKs, ERK1/2 and JNK1/2. Cell treatment with ADP or 2-MeS-ADP also provokes the activation of p53, causing an accumulation of the G1 cyclin-dependent kinase inhibitors p21WAF1 and p27Kip . Inhibition of ZL55 cell proliferation by ADP was completely reversed by inhibiting MEK1/2, or JNK1/2, or PKC-δ, and PKC-α. Through the inhibition of ADP-activated transductional kinases it was found that PKC-δ was responsible for JNK1/2 activation. JNK1/2 has a role in transcriptional up-regulation of p53, p21WAF1/CIP1 , and p27kip1 . Conversely, the ADP-activated PKC-α provoked ERK1/2 phosphorylation. ERK1/2 increased p53 stabilization, required to G1 arrest of ZL55 cells. Concluding, the importance of the study is twofold: first, results shed light on the mechanism of cell cycle inhibition by ADP; second, results suggest that extracellular ADP may inhibit mesothelioma progression.

Keywords: ADP; P2Y1; PKC-α; PKC-δ; human mesothelioma cells; p53.

MeSH terms

  • Adenosine Diphosphate / analogs & derivatives
  • Adenosine Diphosphate / pharmacology*
  • Antineoplastic Agents / pharmacology*
  • Asbestos / adverse effects
  • Cell Cycle Proteins / metabolism
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Dose-Response Relationship, Drug
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Mesothelioma / drug therapy*
  • Mesothelioma / enzymology
  • Mesothelioma / genetics
  • Mesothelioma / pathology
  • Phosphorylation
  • Protein Kinase C-alpha / genetics
  • Protein Kinase C-alpha / metabolism*
  • Protein Kinase C-delta / genetics
  • Protein Kinase C-delta / metabolism*
  • Protein Stability
  • Purinergic P2Y Receptor Agonists / pharmacology*
  • RNA Interference
  • Receptors, Purinergic P2Y1 / drug effects*
  • Receptors, Purinergic P2Y1 / metabolism
  • Signal Transduction / drug effects*
  • Thionucleotides / pharmacology
  • Time Factors
  • Transfection
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Antineoplastic Agents
  • Cell Cycle Proteins
  • Purinergic P2Y Receptor Agonists
  • Receptors, Purinergic P2Y1
  • TP53 protein, human
  • Thionucleotides
  • Tumor Suppressor Protein p53
  • Asbestos
  • methylthio-ADP
  • Adenosine Diphosphate
  • PRKCA protein, human
  • PRKCD protein, human
  • Protein Kinase C-alpha
  • Protein Kinase C-delta
  • Extracellular Signal-Regulated MAP Kinases
  • JNK Mitogen-Activated Protein Kinases